Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors
Mariet C.W. Feltkamp(Leiden University Medical Center), W. Martin Kast(University of Southern California), Sjoerd H. van der Burg(Leiden University Medical Center), Gienke R. Vreugdenhil(Leiden University), Michel Vierboom(Biomedical Primate Research Centre), Jan ter Schegget(Department of Virology), Elisabeth Ras(Leiden University), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands))
Cited by 167
Related Papers
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840